Emtryl

Quick links to important sections

Emtryl

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Emtryl

Quick Facts

Property Description
Active Ingredient Dimetridazole
Pharmacological Class Antiprotozoal Agent, Nitroimidazole Derivative
Form Water-Soluble Powder, Premix, Tablet
Intended Use Context Veterinary Medicine
Origin Synthetic Compound

What is Emtryl and Its Active Ingredient, Dimetridazole?

Emtryl is the commercial designation for a medicine containing the synthetic compound known by its official active ingredient name, Dimetridazole. This primary substance is chemically classified as a nitroimidazole derivative, a specific group of synthetic chemicals recognized for their anti-infective properties. This compound’s action is recognized for its effectiveness against specific microbial challenges in susceptible hosts. Unlike other agents in the imidazole family, Dimetridazole is primarily and historically designated as a specialized veterinary medicine. This classification indicates that the medicine is primarily specialized for anti-parasitic use in non-food-producing animals, distinguishing it from related human pharmaceuticals.

Dimetridazole: The Nitroimidazole Classification and Available Forms

Dimetridazole is formally categorized as an antiprotozoal agent, placing it within the larger domain of antimicrobial compounds that combat specific infectious entities. This classification defines the substance's targeted activity against protozoa (single-celled parasites) and certain anaerobic bacteria, characterizing its specialized role within a host. Dimetridazole's effectiveness is confined to organisms susceptible to the nitroimidazole mechanism; consequently, the medicine’s utility is specific to certain types of infections. For practical administration in veterinary settings, the medicine is commonly manufactured as a water-soluble powder or a premix for incorporation into feed, with administration primarily occurring via the oral route to the animals.

What is the General Purpose of This Specialized Antimicrobial?

The general purpose of this medicine is to act as a selective anti-infective agent to control conditions caused by susceptible microbial pathogens in specific animal groups, for example, controlling outbreaks of histomoniasis in poultry. Its function is based on a targeted cytotoxic action that disrupts the infectious agents at a fundamental level. This mechanism involves the Dimetridazole molecule being metabolically activated inside the microbial cell, where it causes damage to the organisms’ genetic material, leading to the termination of the pathogens' ability to reproduce and survive.

What side effects are possible with Emtryl?

Possible side effects and safety information

The official safety profile for the active ingredient Dimetridazole is structured primarily by regulatory restrictions on its use rather than a detailed list of clinical adverse effects. This framework is governed by authoritative government agencies, including the U.S. Food and Drug Administration and the European Medicines Agency, which focus on safety across the entire nitroimidazole class of antiprotozoal agents.

Regulatory Safety Restrictions

Category Official Regulatory Status
Use Restriction Strictly prohibited from use in all food-producing animal species (e.g., chickens, turkeys, pigs).
Basis for Restriction Non-clinical findings of genotoxicity and potential carcinogenicity observed in laboratory studies.
Exposure Concern Mandatory regulatory focus on reducing the potential for undue hazard to human health from drug residues in the food supply.

Adverse Reaction Classification

Regulatory documents do not provide a frequency-classified list (such as 'common,' 'uncommon,' or 'rare') of clinical side effects for the authorized uses of Dimetridazole. The core safety information addresses systemic hazards and constraints on product use.

  • Serious Regulatory Concerns: Regulatory reviews cite genotoxicity and the potential for tumor production in animals as the critical safety elements that underpin the prohibition in food-producing populations.
  • Population-Specific Note: The medicine is categorized as a drug with no allowable extra-label uses in food animals. Furthermore, specific safety directions are required on product labels to address the potential risk of exposure for individuals handling the product.

This safety structure confirms that the official regulatory concern centers on public health protection and managing human exposure to the compound.

Overdose and Emergency Response

The official regulatory profile for Dimetridazole (Emtryl) overdose is primarily defined by the risk of Central Nervous System (CNS) neurotoxicity, a documented concern for the nitroimidazole class of antimicrobials. Manifestations of overdose or prolonged high-dose exposure, as described in regulatory documents, include significant neurological signs such as ataxia (loss of coordination), tremors, and convulsive seizures. Gastrointestinal effects like vomiting and disorientation are also documented presentations.

Severe overexposure carries the risk of serious or life-threatening outcomes. Officially documented complications include encephalopathy (a form of brain disease) and severe, sometimes irreversible, hepatotoxicity (liver damage). Due to these severe risks, regulatory guidance mandates immediate action: the product must be discontinued right away if neurological symptoms appear.

In any case of suspected massive overdose, medical or veterinary attention must be sought immediately. Official labeling states that no specific antidote is available for gross overdose. Therefore, management is strictly limited to the institution of symptomatic and supportive treatment to address the clinical signs and mitigate potential fatal outcomes. Special consideration is noted for patients with pre-existing hepatic dysfunction, as they may be at increased risk.

Therapeutic Uses of Emtryl

What Emtryl Treats: Main Uses and Benefits

Dimetridazole, the active ingredient in Emtryl, is an anti-protozoal agent relevant for managing specific infectious diseases in targeted animal populations. The medication is generally relevant for easing the symptomatic burden of diseases like Histomoniasis (Blackhead disease) in poultry, various forms of Trichomoniasis in avian and breeding stock, and certain dysentery and hemorrhagic enteritis conditions in pigs.

This therapeutic approach is applied across domains where additional symptomatic support is needed. It is applied in clinical settings that involve acute symptom patterns, such as severe systemic decline and symptoms related to inflammatory or irritative states. The medicine may assist with managing the infectious process and supports general well-being during symptomatic phases. It is commonly used for managing acute intestinal issues, which assists with maintaining functional stability and supports the return of appetite.

In a specific context, this targeted use may also assist with managing the infection linked to functional stability becoming affected in breeding cattle, which contributes to improved comfort during periods of heightened symptoms.


Quick Fact: Relevance for Acute Gastrointestinal and Systemic Symptoms

Eligibility and Restrictions for Use

Who Can and Cannot Use Emtryl (Metronidazole)

This information reflects the official eligibility rules and restrictions defined in government regulatory labeling.

Populations Who Must Not Use Emtryl (Contraindications)

Metronidazole is strictly contraindicated (must not be used) in the following groups:

  • Patients with a known hypersensitivity or allergy to metronidazole or other nitroimidazole medicines.
  • Individuals who have taken disulfiram (a medication for chronic alcoholism) within the last two weeks.
  • Patients with Cockayne Syndrome, due to the high risk of fatal hepatotoxicity (severe liver damage) associated with metronidazole use.

Conditions and Populations Requiring Restricted Use

Use of Emtryl requires special consideration or a dose reduction in specific populations:

  • Severe Hepatic Impairment: Patients with severe liver disease (e.g., Child-Pugh C) typically require a reduced dose and enhanced monitoring for adverse effects.
  • Pregnancy and Breastfeeding: While generally considered low risk, use is often not recommended or is contraindicated during the first trimester of pregnancy for certain indications. For high-dose single regimens, regulatory bodies may advise temporarily interrupting breastfeeding to minimize infant exposure.
  • Newborn Infants: Use in neonates requires careful monitoring because the drug's elimination half-life can be significantly prolonged.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Emtryl

The official regulatory profile for Emtryl (Dimetridazole) does not detail traditional drug-drug interaction tables for the animal host. Instead, the entire interaction profile is defined by mandatory use restrictions related to the human food chain.

Interaction scope

Category Officially Documented Finding
Medicinal product categories with documented interactions None explicitly listed for co-administered medicinal products in the veterinary host.
Mechanistic basis of interactions (only if stated in label) The compound's active metabolites are officially noted to form covalent binding residues that persist in animal tissues, which is the official basis for the human exposure risk.
Timing-based interaction rules (if applicable) Historically required mandatory withdrawal period of at least 6 days between administration and slaughter, intended as a time separation rule to reduce residue risk.
Population-specific interaction notes (if applicable) Prohibited for use in the entire population of food-producing animal species (e.g., cattle, pigs, chickens, turkeys).
Interaction-related restrictions The official prohibition of using Dimetridazole in animals intended for human consumption constitutes the most severe regulatory interaction restriction.

Interaction classifications (high-level)

Interaction severity classification (as defined in official documents): Prohibited Use (Contraindication to the Food Chain).

Interaction-context constraints (as defined in official documents): Restriction is based on the official finding that the substance is potentially genotoxic and carcinogenic, leading to an unacceptable risk to human consumers from residues entering the food supply.

Resulting interaction structure

Official interaction statements:

  • Use of Dimetridazole and its class (Nitroimidazoles) is prohibited in all food-producing animal species.
  • The restriction is based on the persistence and formation of covalent binding residues in tissues.

Connection to the overall interaction profile (2–4 sentences): The regulatory interaction profile for Emtryl is characterized by a population-level contraindication based on residue persistence, an officially documented pharmacokinetic outcome. This structure indicates that the principal concern documented by regulatory bodies is the functional interaction between the substance and the human consumer via the food supply, leading to a permanent and mandatory interaction-related restriction on use.

Mechanism of Action

Reductive Bioactivation: Targeting Anaerobic Metabolism

Dimetridazole's action is initiated by reductive bioactivation within the target microbe. The molecule requires the low-redox potential environment and specialized electron-transfer proteins (like ferredoxins) found only in anaerobic organisms to chemically convert its inactive form into highly toxic nitro radical anions. This selective activation step defines the drug's activity profile by concentrating its mechanism only where it can be physiologically effective—within the microbe, not the host.


Molecular Cascade: Irreversible Genetic Damage

The activated nitro radical anions function as cellular toxins that inflict rapid and irreversible damage by causing covalent modifications and strand breakage to the pathogen's DNA. This molecular damage cascade swiftly prevents the microbe from replicating its genetic material or synthesizing necessary proteins. The resulting physiological consequence is the definitive cytotoxic destruction of the target pathogen.


Mechanistic Boundary: The Role of Oxygen

The efficiency of this entire mechanism is strictly governed by the local oxygen concentration. Oxygen acts as a competing electron sink, diverting the necessary electrons away from Dimetridazole in a process called futile cycling. This means the mechanism's power is maximized in deeply anaerobic tissue environments, and the absence of oxygen is necessary to maintain the mechanism's inherent selectivity, successfully completing the cytotoxic activation cycle.

Dosage and Administration Information

How Emtryl is Used in Official Practice

Emtryl (Dimetridazole) usage is governed by the product's official instructions, which define the administration methods, dosage calculation, and duration based on the treatment goal. The medicine is primarily available as a water-soluble powder or a premix intended for incorporation into the animal's feed or drinking water supply. This formulation mandates the oral route as the standard method of administration for target species, including turkeys and swine.

Dosing and Administration Schedules

Official dosing is typically standardized by stating the required concentration as a percentage within the feed or water, rather than a per-kilogram dose. This approach ensures a continuous level of intake throughout the treatment period. For instance, treatment in turkeys may utilize a concentration of 0.08% in feed, while long-term prevention protocols may require a lower concentration, such as 0.02%.

Administration is classified based on the objective: Therapeutic Use involves short, fixed courses, generally lasting up to 7 days to resolve existing issues. Conversely, Prophylactic Use involves longer courses, potentially lasting up to 10 weeks, aimed at disease prevention. Regardless of the objective, the full course duration must be completed, and a mandatory withdrawal period must be observed immediately afterward to ensure compliance with official residue limits.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section provides an overview of the key studies that have examined the compound's properties and potential applications. It does not provide medical advice or make claims regarding treatment suitability.

Research on Primary Compound X

According to preclinical research, the primary ingredient is a compound exhibiting anti-inflammatory activity in non-human models that has been the subject of several exploratory studies.

Early-Stage Pharmacological Studies

  • Biological Processes: Initial laboratory research focused on understanding the biochemical interactions of the compound. Studies assessed its interaction with biological processes relevant to inflammation.
  • Biokinetics: Early-stage human studies investigated its absorption rate and half-life in the plasma. Researchers monitored how the compound is processed by the body.

Clinical Trials in Musculoskeletal Conditions

  • Joint Function: Research investigated the compound in relation to changes in joint mobility and flexibility, primarily in populations with mild to moderate chronic joint issues. These studies typically use standardized questionnaires and physical assessments.
  • Pain Levels: Studies measured reported pain levels (using visual analog scales) among participants with chronic arthritis over periods ranging from 4 to 12 weeks.
  • Acute Symptoms: Investigations assessed participant-reported symptom intensity during acute flare-ups, monitoring changes during the first 72 hours of use compared to a placebo.

Research on Compound X in Combination Therapy

Further research explored associations when the compound was administered alongside other established treatments, particularly Glucosamine-Chondroitin-MSM (GCM) complexes.

Adjunct Use in Osteoarthritis Management

Clinical trials have evaluated the compound's use as an adjunct therapy with standard GCM treatment over a 6-month period.

  • Symptom Scoring: Studies used tools like the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) to assess participant-reported stiffness, function, and pain.
  • Long-Term Metrics: Researchers explored its association with long-term changes in inflammation and comfort scores beyond the initial treatment period.
  • Clinical Markers: Research investigated the incidence of changes in clinical markers such as specific cytokines or markers of cartilage degradation, in the serum, for participants receiving the combination of compounds.

Association with Concurrent Medication Use

One study monitored whether there is an association between its use and participant-reported NSAID use over a 3-month period. The study's primary objective was to monitor participant-reported changes in concurrent medication use alongside the combination product.

Frequently Asked Questions (FAQ)

Common questions about Emtryl (FAQ)


Q: What condition is Emtryl primarily used to treat in birds and pigeons?

Emtryl, which contains Dimetridazole, is officially indicated in veterinary medicine for treating specific protozoal infections. This includes conditions like histomoniasis (blackhead) in turkeys and trichomoniasis, commonly known as canker, in pigeons where its use is approved. The drug is targeted to fight these types of single-celled parasites in susceptible hosts.


Q: What are the most commonly reported or observed side effects of Emtryl in birds?

While regulatory documents focus on public health restrictions, observed clinical signs in animals treated with drugs in this class (nitroimidazoles) may include systemic effects. These can involve changes such as decreased appetite, listlessness, and gastrointestinal signs like vomiting or diarrhea. With high or excessive concentrations, the product information for this class notes potential neurological signs, such as lack of coordination or tremors.


Q: Is a loss of appetite considered a normal reaction when a bird is on Emtryl?

Yes, regulatory and product information for this class of medicine indicates that a decreased appetite, or anorexia, is listed as a potential clinical reaction. If a bird shows a significant or sustained loss of appetite or other clinical signs, consultation with a qualified professional is generally advised.


Q: What are some common alternative names or brand names for Dimetridazole, the active substance in Emtryl?

The active substance in Emtryl is Dimetridazole, which is its official chemical name. In addition to Emtryl, other commercial names may have been used historically for products containing Dimetridazole, depending on the region and the specific formulation.


Q: What is the difference between Emtryl soluble powder and the tablet form?

The difference relates to the method of administration in veterinary settings. The water-soluble powder is typically mixed into the drinking water or feed for mass administration to treat an entire flock or group of animals. In contrast, the tablet form is generally used for individual animal treatment.


Q: Does Emtryl affect the gut bacteria in birds?

The drug belongs to the nitroimidazole class, which is designed to act selectively against anaerobic organisms, including certain susceptible bacteria and protozoa. Based on the mechanism of action, it is expected to affect some of the microbial populations, including certain types of anaerobic flora, that are present in the digestive tract.


Q: What are the concerns about using Emtryl in birds that are feeding their young?

Official veterinary label warnings often contraindicate the use of nitroimidazoles in nursing and pregnant animals. This restriction is based on general safety concerns within the drug class regarding the potential for unwanted exposure to the young animals.


Q: Can a bird overdose on Emtryl, and what would the signs look like?

Toxicity studies conducted on related species have indicated that high concentrations of Dimetridazole can lead to adverse effects. These effects may include nervous signs, such as lack of muscle control (ataxia) or abnormal head movements, which have been observed during toxicity studies.


Q: Does the age or size of the bird affect how Emtryl works?

General veterinary dosing principles recognize that a drug's efficacy and the rate at which it is eliminated can be influenced by the animal’s body weight, age (especially in very young animals), and physiological state. These factors typically influence the determination of appropriate drug use and elimination rates in animals.


Q: Is Emtryl used to treat conditions in the crop, mouth, or digestive system?

Yes, the official indications for Emtryl include the treatment of diseases like trichomoniasis (canker) in pigeons. This infection commonly manifests in and affects the mouth, the crop, and the upper digestive system of susceptible avian hosts.


Q: Can Emtryl be used as a routine preventative measure, and how often?

The official product labeling specifically outlines administration protocols for both therapeutic (treatment of existing disease) and prophylactic (prevention of disease) uses. Whether the drug is used routinely for prevention is typically determined by specific flock management objectives.


Q: What is the half-life of Dimetridazole (Emtryl) in birds?

Pharmacokinetic studies cited in regulatory reviews report that the elimination half-life for Dimetridazole and its major metabolite can vary by bird species. For example, in laying hens, the half-life of Dimetridazole has been reported to be around 0.45 days.


Q: Are there different concentrations of Dimetridazole in different Emtryl products?

Yes, official dosing standards are often expressed as a percentage concentration within the feed or water, and these concentrations vary based on the goal of use. For instance, a higher concentration might be used for short-term treatment than for longer-term prevention protocols.


Q: Is it normal if my bird seems a little lethargic after the first dose of Emtryl?

Tiredness or listlessness is a general sign of systemic drug action that can be observed in animals receiving a nitroimidazole drug. This symptom is generally recognized as a potential clinical reaction to this class of medication.


Q: What is the difference between Emtryl and Ronidazole in terms of its purpose?

Both Dimetridazole (Emtryl) and Ronidazole belong to the same nitroimidazole class of drugs. This means they share the common primary purpose of acting as anti-protozoal agents in veterinary medicine to target specific parasitic infections.


Q: Does Emtryl have to be mixed with feed or can it only be given in water?

According to official product labeling, Emtryl is commonly manufactured as either a water-soluble powder or a premix. These forms are intended for oral administration by incorporating the medicine into the animal's drinking water supply or into its feed.

--UNSAFE

Q: Can Emtryl be used for both sick birds and healthy birds in the same flock?

The official dosing and administration schedules for Emtryl include protocols for 'Prophylactic Use.' This use is aimed at disease prevention in a group of animals that may not yet be showing clinical signs but are considered to be at risk of infection.


Q: What is 'crop canker' and how does Emtryl help to resolve it?

Crop canker is the common name for an infection caused by the protozoan Trichomonas gallinae, which affects the upper digestive system. As a nitroimidazole, Dimetridazole acts by being chemically activated inside the pathogen, causing damage to its DNA and leading to the destruction of the infectious agent.


Q: How is the anti-protozoal action of Emtryl linked to its chemical structure as a nitroimidazole?

The chemical structure, specifically the nitroimidazole group, is critical to the drug’s function. It is selectively reduced by the pathogen's internal enzymes, which converts the inactive drug into highly reactive, toxic free radicals that ultimately cause irreversible damage to the protozoan's DNA.


Q: Does Emtryl affect a bird's ability to fly or its general behavior?

High concentrations of this drug class have been associated with nervous signs in treated animals, including a lack of coordination (ataxia) and abnormal head movements. These symptoms would directly impact a bird's general behavior and ability to move or fly normally.


Q: Is Emtryl known to have a strong taste that might deter birds from drinking it?

Nitroimidazoles are generally known in veterinary practice to have a distinct, often bitter, taste. This can be a practical concern when administering the medicine in the drinking water, as palatability issues may cause animals to reduce their water intake.


Q: Is there a withdrawal period for game birds or poultry treated with Emtryl?

The use of Dimetridazole is strictly prohibited by regulatory bodies in all food-producing animal species, which includes poultry and game birds intended for human consumption. This restriction is based on ensuring public health protection from potential drug residues in the food supply.

How should Emtryl be stored and disposed of?

How to Store and Dispose of Emtryl (Metronidazole)

Emtryl should be stored at Controlled Room Temperature, ideally between 59°F and 77°F (15°C and 25°C). It is critical to protect the medication from light during storage. For oral tablets, the product must be dispensed in a well-closed container with a child-resistant closure to prevent accidental ingestion by children.

Specific in-use stability periods after opening or reconstitution are generally not defined for this product. The extended-release tablet formulation requires storage in a dry place.

For disposal of unused or expired Emtryl, the preferred method is to utilize a community drug take-back program. If this option is unavailable, the medicine should be mixed with an undesirable substance, placed in a sealed bag, and thrown into the household trash. Do not flush the medication down a toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Emtryl found in:

A-Z Index: